SUNNYVALE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — 23andMe Holding Co. (“23andMe”), a leading consumer genetics and research company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-00610 for the treatment of advanced solid tumors. 23ME-00610 is 23andMe’s first wholly-owned immuno-oncology (I/O) antibody to enter the clinic. The … Continue reading 23andMe: a clinical trial for Immuno-oncology Antibody